Top Stories
AstraZeneca signs $2 billion agreement with Quell to develop cell therapies
Global Banking & Finance Review®
Company
(Reuters) – AstraZeneca said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.
(Reuters) – AstraZeneca said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.
The agreement includes developing, manufacturing and commercialising cell therapies that have the potential to be curative in type 1 diabetes and inflammatory bowel disease indications, the drugmaker said in a statement.
UK-based Quell will receive $85 million upfront from AstraZeneca, and is also eligible to receive over $2 billion for further development and commercialisation milestones, the company added.
(Reporting by Radhika Anilkumar in Bengaluru; Editing by Rashmi Aich)
A partnership is a business arrangement where two or more individuals or entities collaborate to manage and operate a business, sharing profits, losses, and responsibilities.
An investment is the allocation of resources, usually money, to generate income or profit. It can involve purchasing assets like stocks, bonds, or real estate.
Innovation refers to the process of creating new ideas, products, or methods that improve efficiency, effectiveness, or competitive advantage in a market.
Explore more articles in the Top Stories category
